- Home
- CPRX vs GOF Comparison
CPRX vs GOF Comparison
Compare CPRX & GOF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CPRX
- GOF
- Stock Information
- Founded
- CPRX 2002
- GOF 2006
- Country
- CPRX United States
- GOF United States
- Employees
- CPRX N/A
- GOF N/A
- Industry
- CPRX Biotechnology: Pharmaceutical Preparations
- GOF Finance/Investors Services
- Sector
- CPRX Health Care
- GOF Finance
- Exchange
- CPRX Nasdaq
- GOF Nasdaq
- Market Cap
- CPRX 2.5B
- GOF 2.2B
- IPO Year
- CPRX 2006
- GOF N/A
- Fundamental
- Price
- CPRX $22.78
- GOF $15.30
- Analyst Decision
- CPRX Strong Buy
- GOF
- Analyst Count
- CPRX 7
- GOF 0
- Target Price
- CPRX $32.86
- GOF N/A
- AVG Volume (30 Days)
- CPRX 1.4M
- GOF 789.2K
- Earning Date
- CPRX 02-26-2025
- GOF 01-01-0001
- Dividend Yield
- CPRX N/A
- GOF 15.42%
- EPS Growth
- CPRX 114.68
- GOF N/A
- EPS
- CPRX 1.18
- GOF N/A
- Revenue
- CPRX $460,482,000.00
- GOF N/A
- Revenue This Year
- CPRX $23.98
- GOF N/A
- Revenue Next Year
- CPRX $18.27
- GOF N/A
- P/E Ratio
- CPRX $19.33
- GOF N/A
- Revenue Growth
- CPRX 32.17
- GOF N/A
- 52 Week Low
- CPRX $13.12
- GOF $10.96
- 52 Week High
- CPRX $24.27
- GOF $16.76
- Technical
- Relative Strength Index (RSI)
- CPRX 56.81
- GOF 44.96
- Support Level
- CPRX $21.23
- GOF $15.15
- Resistance Level
- CPRX $23.26
- GOF $15.36
- Average True Range (ATR)
- CPRX 1.14
- GOF 0.15
- MACD
- CPRX 0.20
- GOF 0.02
- Stochastic Oscillator
- CPRX 74.85
- GOF 40.26
About CPRX Catalyst Pharmaceuticals Inc.
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with Lambert-Eaton myasthenic syndrome.
About GOF Guggenheim Strategic Opportunities Fund of Beneficial Interest
Guggenheim Strategic Opportunities Fund is a diversified, closed-end management investment company. The investment objective of the firm is to maximize total return through a combination of current income and capital appreciation. The Fund seeks to combine a credit-managed fixed-income portfolio with access to a diversified pool of alternative investments and equity strategies.